MARCELO DER TOROSSIAN Torres lifted the clear plastic cover off of a petri dish one morning last June. The dish, still warm from its sleepover in the incubator, smelled of rancid broth. Inside it sat a rubbery bed of amber-colored agar, and on that bed lay neat rows of pinpricks—dozens of colonies of drug-resistant bacteria sampled from the skin of a lab mouse.
Torres counted each pinprick softly to himself, then did some quick calculations. Untreated for the infection, the samples taken from an abscess on the mouse had yielded billions of superbugs, or antibiotic-resistant bacteria. But to his surprise, some of the other rows on the petri dish seemed empty. These were the ones corresponding to samples from mice that received an experimental treatment—a novel antibiotic.
Introduction La cybersécurité est devenue une priorité stratégique pour toutes les entreprises, grandes ou petites.…
Cybersécurité : les établissements de santé renforcent leur défense grâce aux exercices de crise Face…
La transformation numérique du secteur financier n'a pas que du bon : elle augmente aussi…
L'IA : opportunité ou menace ? Les DSI de la finance s'interrogent Alors que l'intelligence…
Telegram envisage de quitter la France : le chiffrement de bout en bout au cœur…
Sécurité des identités : un pilier essentiel pour la conformité au règlement DORA dans le…
This website uses cookies.